Item 2.02.
|
Results of Operations and Financial Condition.
|
On November 14, 2016, Aldeyra
Therapeutics, Inc. (Aldeyra) issued a press release and is holding a conference call regarding its financial results for the quarter ended September 30, 2016. The press release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated by reference herein.
Various statements to be made during the conference call are forward-looking
statements under the securities laws, including, but not limited to, statements regarding Aldeyras plans for its product candidates. In some cases, you can identify forward looking statements by terms such as, but not limited to,
may, might, will, objective, intend, should, could, can, would, expect, believe, anticipate,
project, target, design, estimate, predict, potential, plan or the negative of these terms, and similar expressions intended to identify forward-looking statements.
Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could
cause actual results to differ materially from those reflected in Aldeyras forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyras clinical trials, the timing and success of
preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyras product candidates, and the labeling for
any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyras product candidates; the size and growth of the potential markets for Aldeyras product candidates and the ability to serve those
markets; Aldeyras expectations regarding Aldeyras expenses and revenue, the sufficiency of Aldeyras cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyras product
candidates; Aldeyras expectations regarding competition; Aldeyras anticipated growth strategies; Aldeyras ability to attract or retain key personnel; the anticipated trends and challenges in Aldeyras business and the market
in which it operates; and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Aldeyras Annual Report on Form
10-K for the year ended December 31, 2015 and Aldeyras Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, which are on file with the Securities and Exchange Commission (SEC) and available on the SECs website at
www.sec.gov. Additional information will also be set forth in those sections of Aldeyras Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, which will be filed with the SEC in the fourth quarter of 2016.
In addition to the risks described above and in Aldeyras other filings with the SEC, other unknown or unpredictable factors also could
affect Aldeyras results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information conveyed on the conference call is provided only as of the date of the call, and
Aldeyra undertakes no obligation to update any forward-looking statements presented on the call on account of new information, future events, or otherwise, except as required by law.
The information in Item 2.02 of this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as expressly set forth by specific reference in such a filing.